Concepedia

Publication | Closed Access

Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed

DOI

33

Citations

20

References

2017

Year

Florie Bottet, B. Peyronnet, R. Boissier, B. Reiss, Jean Gabriel Previnaire, A. Manunta, J. Kerdraon, A. Ruffion, L. Lenormand, B. Perrouin Verbe,
Neurourology and Urodynamics

Abstract

Most patients refractory to Botox® (56.14%) draw benefits from the switch to Dysport®.

References

YearCitations

Page 1